08:55 AM EDT, 07/12/2024 (MT Newswires) -- AbbVie ( ABBV ) said Friday that it has submitted new indication applications to the US Food and Drug Administration and the European Medicines Agency for its drug upadacitinib for the treatment of adult patients with giant cell arteritis.

Giant cell arteritis is an autoimmune disease that causes inflammation of the arteries in the head.

The submissions are based on data from a late-stage study that evaluated the safety and efficacy of upadacitinib in patients with giant cell arteritis, the company said.

Price: 170.37, Change: +0.46, Percent Change: +0.27